BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share

BioRestorative Therapies, Inc.

Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.
Net proceeds to fund BRTX-100 clinical trials, ThermoStem Program R&D, and general corporate purposes.
Titan Partners Group acting as sole placement agent with 6% cash fee and up to $60K expense reimbursement.
Shares offered under effective S-3 shelf registration (File No. 333-269631).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioRestorative Therapies, Inc. entered into Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2023-07-11).

Action: entry
Agreement: underwriting
Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
Effective: 2023-07-11

Exact text from the filing

the Company entered into a placement agency agreement dated July 11, 2023 (the “Placement Agency Agreement”), with Titan Partners Group LLC, a division of American Capital Partners, LLC

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioRestorative Therapies, Inc. entered into Purchase Agreement with several institutional buyers and accredited investors valued at approximately $2.1 million (effective 2023-07-11).

Action: entry
Agreement: equity purchase
Counterparty: several institutional buyers and accredited investors
Value: approximately $2.1 million
Effective: 2023-07-11

Exact text from the filing

On July 11, 2023, BioRestorative Therapies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with several institutional buyers and accredited investors (the “Purchasers”)

View on SEC.gov

Browse all material agreements →

BioRestorative Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001021771-23-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.